Imucort24 mg

FDA-Approved Indication: Duchenne Muscular Dystrophy

Imucort is FDA-approved (established indication) for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Imucort is used to help slow the decline in muscle strength associated with this genetic muscle-wasting disease.

Broader Anti-Inflammatory and Immunosuppressive Uses (Guideline-Supported/Off-Label Outside the US)

Outside the United States - including in Bangladesh, where Imucort is widely prescribed - Imucort is also used as a general corticosteroid for a broad range of inflammatory, allergic, and autoimmune conditions. These uses are guideline-supported or established in regional clinical practice but are not part of the US FDA-approved label for Imucort:

• Allergic/hypersensitivity conditions: anaphylaxis (adjunct), severe hypersensitivity reactions, acute and chronic bronchial asthma exacerbations
• Rheumatologic/connective tissue disorders: rheumatoid arthritis, juvenile chronic (idiopathic) arthritis, polymyalgia rheumatica, systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease, polyarteritis nodosa, sarcoidosis
• Dermatologic conditions: pemphigus, bullous pemphigoid, pyoderma gangrenosum
• Renal disorders: minimal change nephrotic syndrome, acute interstitial nephritis
• Cardiac: rheumatic carditis
• Gastrointestinal: ulcerative colitis, Crohn's disease (adjunct)
• Ophthalmic: uveitis, optic neuritis
• Hematologic: autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura
• Oncologic (adjunct): acute lymphoblastic leukemia, malignant lymphoma, multiple myeloma, as part of combination chemotherapy regimens
• Transplantation: immunosuppression to prevent/treat organ transplant rejection

Dosing and duration for each condition should be individualized by a qualified physician.

Each Deflazacort tablet contains Deflazacort INN as the active ingredient, available in strengths of 6 mg, 18 mg, 24 mg, 30 mg, and 36 mg. Deflazacort is also available as an oral suspension (22.75 mg/mL) and, in some markets, an oral syrup (6 mg/5 mL).

Imucort is a corticosteroid (glucocorticoid) medicine used to reduce inflammation and calm an overactive immune system. In the United States, Imucort is FDA-approved specifically for Duchenne muscular dystrophy in children aged 2 years and older, where Imucort helps preserve muscle strength. In many other countries, including Bangladesh, Imucort is also used more broadly for allergic, autoimmune, and inflammatory conditions such as asthma, arthritis, and certain kidney and blood disorders. Imucort works by binding to glucocorticoid receptors and suppressing inflammatory pathways throughout the body. Because Imucort affects multiple body systems, Imucort should only be used under close medical supervision, with the dose tailored to each patient's condition.

Corticosteroid (Glucocorticoid)

Deflazacort is a prodrug that is rapidly converted by esterases in the body to Deflazacort's pharmacologically active metabolite, 21-desDFZ. This active metabolite binds to the glucocorticoid receptor, producing anti-inflammatory and immunosuppressive effects, including inhibition of phospholipase A2 (which reduces the production of inflammatory mediators) and suppression of the release of pro-inflammatory cytokines and other immune mediators. Through these actions, Deflazacort reduces inflammation, edema, and immune-mediated tissue damage across multiple organ systems.

• Take Imucort by mouth, generally once daily, at approximately the same time each day.
• Imucort tablets and oral suspension may be taken with or without food; taking Imucort with food or a light meal may help reduce stomach upset.
• Do not take Imucort with grapefruit or grapefruit juice, as grapefruit can increase Imucort levels in the body.
• Shake the Imucort oral suspension well before measuring each dose, and use an accurate oral dosing syringe or cup, not a household spoon.
• Swallow Imucort tablets whole, or as directed by your doctor or pharmacist.
• Do not stop taking Imucort suddenly, especially after using Imucort for more than a few days - the dose of Imucort must be tapered down gradually under medical supervision.
• If a dose of Imucort is missed, take the missed dose as soon as remembered unless it is almost time for the next dose of Imucort; do not double the dose.
• Keep all follow-up appointments so your doctor can monitor your response to Imucort and adjust the dose of Imucort as needed.

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice): These drugs can significantly increase blood levels of the active metabolite of Imucort by inhibiting the breakdown of Imucort; the dose of Imucort may need to be reduced to about one-third of the usual dose.
• CYP3A4 inducers (e.g., rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbitone, efavirenz): These drugs speed up the breakdown of Imucort's active metabolite, reducing the effectiveness of Imucort; concurrent use with strong inducers should generally be avoided.
• NSAIDs (e.g., ibuprofen, diclofenac, aspirin): Combining NSAIDs with Imucort increases the risk of gastrointestinal irritation, ulceration, and bleeding.
• Potassium-depleting diuretics and other drugs affecting potassium (e.g., furosemide, thiazide diuretics, amphotericin B): Imucort increases potassium excretion, so combined use with these drugs raises the risk of hypokalemia; potassium levels should be monitored.
• Antidiabetic medications (insulin, oral hypoglycemic agents): Imucort can raise blood glucose levels and reduce the effectiveness of antidiabetic medications, so doses of diabetes medications may need to be adjusted.
• Live or live-attenuated vaccines: Imucort suppresses the immune response, so live vaccines should not be given during Imucort therapy at immunosuppressive doses; vaccination should be completed before starting Imucort where possible.
• Other immunosuppressants (e.g., other corticosteroids, methotrexate, cyclosporine): Combined use of these drugs with Imucort increases the overall risk of infection due to additive immune suppression.
• Neuromuscular blocking agents (e.g., pancuronium): Concurrent use of neuromuscular blocking agents with Imucort has been associated with an increased risk of acute myopathy, particularly affecting respiratory muscles.

Common Side Effects

• Cushingoid appearance (rounded face, fat redistribution)
• Weight gain and increased appetite
• Hirsutism (excess hair growth)
• Upper respiratory tract infection, nasopharyngitis, cough
• Irritability and behavioral changes
• Abdominal discomfort, nausea, constipation
• Frequent urination (pollakiuria)
• Skin changes: acne, erythema, striae, skin thinning
• Headache, back pain

Serious Side Effects - Seek Medical Attention

• Signs of adrenal insufficiency (severe fatigue, weakness, dizziness, low blood pressure, vomiting) - especially if Imucort is stopped abruptly
• Signs of infection (fever, sore throat, unusual fatigue) that may be masked by Imucort
• Severe stomach pain, black or bloody stools, vomiting blood (possible GI ulcer/perforation)
• Vision changes, eye pain (possible cataracts, glaucoma, or increased intraocular pressure)
• Severe mood changes, depression, confusion, or psychosis
• Signs of blood clots (leg swelling/pain, chest pain, shortness of breath)
• Bone pain or fractures (possible osteoporosis or avascular necrosis)
• Severe skin reaction (blistering, peeling skin, rash with fever) - possible toxic epidermal necrolysis
• Muscle weakness, especially affecting breathing muscles
• Signs of heart failure (swelling, shortness of breath, rapid weight gain)
• Symptoms of high blood sugar (increased thirst, frequent urination, confusion)

Pregnancy

Imucort readily crosses the placenta. As with other corticosteroids, use of Imucort during pregnancy has been associated with a small increase in the risk of orofacial clefts when Imucort is used in the first trimester, and with intrauterine growth restriction and lower birth weight when Imucort is used later in pregnancy. Imucort should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, and only under close medical supervision. Infants born to mothers who received substantial doses of Imucort during pregnancy should be monitored for signs of adrenal insufficiency.

Breastfeeding

Corticosteroids, including Imucort, pass into breast milk. Low to moderate doses of Imucort are generally considered unlikely to cause adverse effects in a breastfed infant, but higher or prolonged doses of Imucort could theoretically affect infant growth or adrenal function. A doctor should weigh the mother's need for Imucort against the possible effects on the breastfed infant, and the infant should be monitored if the mother is taking Imucort.

• Adrenal suppression and tapering (do not stop abruptly): Long-term use of Imucort suppresses the body's natural cortisol production (HPA axis suppression). Stopping Imucort suddenly after prolonged use can cause acute adrenal insufficiency, which can be life-threatening; the dose of Imucort must always be reduced gradually under medical supervision.
• Increased risk of infection: Imucort suppresses the immune system, increasing susceptibility to viral, bacterial, fungal, and parasitic infections, and can mask the usual signs of infection (such as fever), delaying diagnosis and treatment.
• Osteoporosis and growth suppression: Long-term Imucort use decreases bone mineral density, increasing the risk of fractures in adults, and can suppress linear growth in children; bone health and growth in children should be monitored during prolonged Imucort therapy.
• Cushingoid effects: Prolonged use of Imucort commonly causes a Cushingoid appearance (facial rounding, central weight gain, purple striae) and, in severe cases, Cushing's syndrome with associated metabolic and psychiatric effects.
• Hyperglycemia: Imucort can raise blood glucose levels and unmask or worsen diabetes mellitus; blood glucose should be monitored, particularly in patients with existing diabetes or risk factors for diabetes.
• Ophthalmic effects: Prolonged Imucort use (more than 6 weeks) can cause posterior subcapsular cataracts, glaucoma, and increased intraocular pressure; regular eye examinations are recommended during long-term Imucort therapy.
• Cardiovascular and fluid effects: Imucort can cause fluid and salt retention, elevated blood pressure, and potassium loss; Imucort should be used with caution in patients with hypertension, heart failure, or renal impairment.
• Gastrointestinal risk: Imucort should be used with caution in patients with active or prior peptic ulcer disease, diverticulitis, or ulcerative colitis, due to an increased risk of GI perforation or bleeding with Imucort.
• Psychiatric effects: Imucort may cause mood swings, insomnia, anxiety, depression, or, rarely, psychosis, particularly at higher doses of Imucort.
• Serious skin reactions: Rare but serious skin reactions, including toxic epidermal necrolysis, have been reported with Imucort; discontinue Imucort and seek medical attention if a severe skin reaction occurs.
• Live vaccines: Live or live-attenuated vaccines should not be given to patients receiving immunosuppressive doses of Imucort.
• Use with caution in specific conditions: Imucort should be used cautiously in patients with myasthenia gravis, epilepsy, hypothyroidism, ocular herpes simplex, or a history of psychiatric illness.

There is no specific antidote for Imucort overdose. In cases of acute overdose of Imucort, treatment with gastric lavage or induced emesis may be considered, but only if directed by a healthcare professional or poison control - do not induce vomiting on your own unless instructed to do so. Management is otherwise supportive and symptomatic. Chronic overexposure to Imucort (excessive dosing over time) may require temporary dose reduction or a switch to alternate-day dosing under medical guidance. If Imucort overdose is suspected, contact emergency medical services or a poison control center immediately.

Store Imucort according to the product label. In general, keep Imucort in a cool, dry place below 25°C, protected from light and moisture, and out of the reach of children. Do not use Imucort after the expiry date printed on the pack.

Children

Imucort is FDA-approved for Duchenne muscular dystrophy in children 2 years of age and older, and is also used more broadly for pediatric inflammatory and autoimmune conditions. Long-term corticosteroid use, including use of Imucort, can suppress growth in children; height and growth should be monitored regularly during prolonged Imucort therapy, and growth typically resumes after Imucort is discontinued in most cases. The oral suspension formulation of Imucort (which may contain benzyl alcohol) should not be used in infants under 2 years of age.

Elderly

No specific dose adjustment of Imucort is required based on age alone in elderly patients, but elderly patients receiving Imucort should be monitored closely, as age-related conditions such as osteoporosis, diabetes, and hypertension can make the adverse effects of Imucort more serious.

Renal Impairment

No specific dose adjustment of Imucort is generally required in renal impairment; standard precautions for corticosteroid use apply.

Hepatic Impairment

In patients with significant hepatic impairment, blood levels of Imucort's active metabolite may increase; Imucort should be used with caution and the dose of Imucort monitored carefully in these patients.

Diabetic Patients

Imucort can raise blood glucose levels; patients with diabetes may need closer glucose monitoring and adjustment of their antidiabetic medications while taking Imucort.

For acute conditions (such as a severe allergic reaction or an asthma exacerbation), Imucort is typically used as a short course at a higher dose, then tapered and stopped once the condition resolves. For chronic conditions, including Duchenne muscular dystrophy and long-term autoimmune or inflammatory diseases, Imucort is often continued for months to years at the lowest effective dose. Whenever Imucort has been used for more than a few days, Imucort must be tapered off gradually under medical supervision rather than stopped suddenly, to allow the body's own cortisol production to recover and to avoid adrenal insufficiency.

Corticosteroid; Glucocorticoid; Anti-inflammatory and immunosuppressive agent

Deflazacort is a prodrug converted to Deflazacort's active metabolite, 21-desDFZ, which binds to the glucocorticoid receptor. This receptor binding modulates gene transcription, reducing the production of inflammatory mediators (including inhibition of phospholipase A2) and suppressing the migration and activity of immune cells, resulting in anti-inflammatory and immunosuppressive effects.

Imucort is FDA-approved for the treatment of Duchenne muscular dystrophy in children 2 years of age and older, based on clinical trial data in boys aged 5 to 15 years, with safety and efficacy in younger children (2 to 5 years) extrapolated from this data. Imucort is also used more broadly in pediatric patients outside the US for conditions such as juvenile chronic (idiopathic) arthritis, nephrotic syndrome, and acute severe asthma, generally at doses of 0.25-1.5 mg/kg/day depending on the condition. Because long-term use of Imucort and other corticosteroids can suppress linear growth in children, height, weight, and growth velocity should be monitored regularly throughout Imucort treatment, and a pediatric specialist should be involved in long-term management.